TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Process: The process (P1) is carried out in a solvent selected from ether, ketone and/or water, where the solvent is a mixture of solvents comprising acetone and water. In the process (P1), the compound (I) is subjected to an additional recrystallization step, where the recrystallization takes place in a solvent and/or anti-solvent selected from acetic acid, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidone, dimethylsulfoxide and/or acetonitrile; the recrystallization takes place in a mixture of dimethylsulfoxide and acetonitrile; and the 5-chlorothiophene-2-carboxylic acid batch used contains less than 0.15 (preferably less than 0.10) wt./wt.% of each of the following compounds: thiophene-2-carboxylic acid, 3-chlorothiophene-2-carboxylic acid, 4-chlorothiophene-2-carboxylic acid, 3,4- dichlorothiophene-2-carboxylic acid, 3,5-dichlorothiophene-2-carboxylic acid and 4,5-dichlorothiophene-2-carboxylic acid. In the process (P2), the batch or the pharmaceutical composition are only validated for distribution when they contain less than 0.001 wt./wt.% of the compound (A); and the batch or the pharmaceutical composition are only validated for distribution when they contain less than 0.15 (preferably less than 0.10, especially less than 0.05, particularly less than 0.01) wt./wt.% of the compound (B). The process (P3) involves a) providing a reference sample comprising rivaroxaban and at least one reference marker selected from the compound (A) and compound (B); b) carrying out HPLC on the reference sample to determine the relative retention time compared to the retention time of the rivaroxaban of each one of the reference marker present in the reference sample; c) carrying out HPLC on the test sample; and d) comparing relative retention times determined in steps (b) and (c); where, if there is observed a relative retention time in step (c) substantially the same as the relative retention time of the compound (A), then test sample comprises the compound (A) as an impurity, and if there is observed a relative retention time in step (c) substantially the same as the relative retention time of the compound (B), then test sample comprises the compound (B) as an impurity. The process (P3) involves a1) providing a reference sample comprising rivaroxaban and at least one reference marker selected from the compound (A) and the compound (B); b1) carrying out thin layer chromatography (TLC) on the reference sample to determine the relative retention factor on a chromatographic support compared to that of the rivaroxaban of each one of the reference markers present in the reference sample; c1) carrying out TLC on the test sample; and d1) comparing the relative retention factors determined in steps (b1) and (c1), where if there is observed on the chromatographic support a relative retention factor in step (c1) substantially the same as the relative retention factor of the compound (A), then test sample comprises the compound (A) as an impurity, and if there is observed on the chromatographic support a relative retention time in step (c1) substantially the same as the relative retention time of Compound B, then test sample comprises compound (B) as an impurity. The process (P4) involves: a3) providing a test sample of rivaroxaban containing an unknown concentration of the compound (A) and/or the compound (B); b3) providing at least one reference sample having a known concentration of Compound A and/or Compound B; c3) subjecting the test sample and the reference sample to chromatographic separation; d3) obtaining chromatographic quantitative measurements for Compound A and/or Compound B in the test sample and the reference sample; and e3) calculating the amount of Compound A and/or Compound B in the test sample from the measurements of step (d3). The process (P4) involves: a4) providing a test sample of rivaroxaban containing an unknown concentration of Compound A and/or Compound B; b4) providing at least one reference sample having a known concentration of Compound A and/or Compound B; c4) subjecting the test sample and the reference sample to HPLC; d4) measuring the area or height of peaks obtained for Compound A and/or Compound B, in the test sample and the reference sample; and e4) calculating the concentration of Compound A and/or Compound B, in the test sample from the measurements of step (d4). In the process (P5), the compound (IV)/carbonyl activated compound molar ratio is 2/1. The process (P5) is carried out in the presence of a base in a solvent. In the process (P6), the compound (III) is reacted with a sulfide salt selected from lithium sulfide, sodium sulfide, potassium sulfide, and/or ammonium sulfide; the compound (III) is reacted with a hydrosulfide salt selected from lithium hydrosulfide, sodium hydrosulfide, potassium hydrosulfide, and/or ammonium hydrosulfide; the activating agent comprises any suitable agent for the activation of carboxylic acids in the formation of amides (L1). In the process (P6), both the step (i) and step (ii) are carried out in the presence of a solvent; the solvent in step (i) is a mixture of acetonitrile and water, and the solvent in step (ii) is a mixture of acetonitrile and ethyl acetate; and the step (ii) is carried out in the presence of a base, where the base is triethylamine. Preferred Compounds: The compound (IV) is in the form of free base; or in the form of its salt, where the salt is the sulfate (2:1). The obtained rivaroxaban (I) is in crystalline Form I. Preferred Components: The organic base is N,N-diisopropylethylamine (DIPEA). The base is an organic base and the solvent comprises tetrahydrofuran, dioxane, diethylether, diisopropylether, cyclopentyl methyl ether, 2-methyltetrahydrofuran or methyl tert-butyl ether, where the organic base is triethylamine and the solvent is tetrahydrofuran. The amides (L1) are selected from thionyl chloride, N,N'-carbonyldiimidazole (CDI), dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-ethyl-3-(3'- dimethylaminopropyl)carbodiimide (EDC or WSC), 1-propanephosphonic acid cyclic anhydride (T3P), 2-(7-aza-1H-benzotriazole-1-yl)- 1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluorophosphate (TBTU), benzotriazole-1-yl-oxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), benzotriazole-1-yl-oxytrispyrrolidinophosphonium hexafluorophosphate (PyBOP), and/or (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate (COMU). The activating agent is 1-propanephosphonic acid cyclic anhydride (T3P). ACTIVITY - Thrombolytic. No biological data given.    MECHANISM OF ACTION - Clotting factor Xa inhibitor.    ADMINISTRATION - The composition is administered in the form of oral suspension, coated tablets, non-coated tablets, orodispersible tablets, pellets, pills, granules, capsules, or mini-tablets in capsules (claimed). No dosage details given.    EXAMPLE - (S)-4-(4-(5-(Aminomethyl)-2-oxo-1,3-oxazolidin-3-yl)phenyl)morpholin-3-one sulfate (2:1) (16.4 g), was suspended in a mixture of water (83.8 ml) and acetone (29.6 ml). After cooling down to 5-10 degrees C, N,N-diisopropylethylamine (20.2 ml) was added dropwise while keeping the temperature within 5-10 degrees C. The solution of 5-chlorothiophene-2-carbonyl chloride (65.2 mmol) in toluene was added at this point over the resulting solution, while maintaining the temperature of 5-10 degrees C. Copious precipitation was observed during the addition. The addition vessel was washed down with toluene (7.4 ml). The resulting creamy, off-white suspension was heated to 20-25 degrees C and stirred at this temperature for 1 hour. Then, acetone (37.8 ml) was added and the resulting suspension was heated to 45-50 degrees C and stirred at this temperature for 30 minutes. After work up, crude rivaroxaban (21 g; purity: 98.86%) was obtained as an off-white solid. The crude rivaroxaban (20.6 g) was suspended in a mixture of acetonitrile (103 m) and dimethylsulfoxide (61.8 ml). The suspension was heated to reflux (about 95 degrees C) until complete dissolution was observed. The solution was then cooled down to 5-10 degrees C and stirred at this temperature for about 1 hour. After work up, rivaroxaban (18.1 g; purity: 99.65%) was obtained.